Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

NCT06173726 is registered in ClinicalTrials.gov with BioSyngen Pte Ltd as lead sponsor.

NCT NCT06173726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06173726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
Lead sponsor
BioSyngen Pte Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 5, 2023
Completion date
December 5, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic liver cancer